Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this exciting learning session on managing Ph negative Acute lymphoblastic leukemia in adults.
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that progresses rapidly without treatment. It can reoccur after being in remission from previous treatment. It has been noted that refractory ALL did not respond to treatment indicating the previous treatments did not kill enough leukemia cells (blasts) to reach complete remission.
Ph-positive ALL is a special type of ALL in which a genetic mutation is observed in the Philadelphia chromosome. In the case of Ph-negative ALL, genetic disparities are also observed and most importantly in Ph neg ALL there is a disproportionate survival rate among the patients.
Managing Ph neg ALL often becomes difficult, however, the procedures of management of Philadelphia chromosome (Ph)–negative acute lymphoblastic leukemia (ALL) have changed dramatically in recent years leading to a positive vibe for the situation.
Therefore, have overall knowledge regarding the management of Ph negative ALL. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
AI-based liquid biopsy shows promise for detecting brain cancer
2.
Novel probes to label macrophages associated with cancer progression using a selective dye
3.
A Lot Can Be Said About You by Including Yourself in Photos.
4.
New methods show how fast breast cancers grow and how surgery delays affect cancer staging
5.
Telehealth in the pandemic era resulted in fewer therapy interruptions.
1.
The Benefits and Risks of Cervical Conization
2.
Impact of Hormone Therapy Cessation on Tumor Growth: Case Study of Ki-67 Reduction
3.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
4.
The Immune Revolution: Neoantigen Vaccines and the Dawn of Personalized Cancer Therapy in 2025
5.
A New Hope: Exploring the Benefits of Exenteration for Cancer Patients
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
2.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
3.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
5.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation